Literature DB >> 25304998

An unusual presentation of NK/T-cell lymphoma, nasal-type in the United States.

Sarah M Kidwai1, Arjun K Parasher2, Fred Y Lin2.   

Abstract

INTRODUCTION: NK/T-cell lymphoma (NKCL), nasal-type is rare in the United States, representing only 1.5% of non-Hodgkin lymphomas. Classically, patients initially present with nasal obstruction (70%), caused by invasion of the localized lesion into the sinuses and nasal cavities. Initial presentation with persistent sore throat and odynophagia due to oropharyngeal tumor extension is rare, and thus, is often overlooked as viral or bacterial pharyngitis. By studying a case of NKTCL nasal type, we emphasize the need to apply high clinical suspicion for NKTCL, nasal type for early diagnosis and improved survival.
METHODS: A case report of a rare presentation of NKTCL, nasal-type is discussed. A literature review is provided to define clinical signs crucial for early diagnosis, appropriate work-up, and expedient treatment of this aggressive, rapidly progressive malignancy.
RESULTS: In the present case, a 25year-old healthy male presented with a 2-week history of sore throat and odynophagia. On exam, the patient had an ulcerative lesion of the soft palate, an enlarged uvula, and tonsillar exudate with tender submandibular lymphadenopathy. After the patient failed to respond to antibiotic therapy for presumptive pharyngitis, a biopsy of the oropharyngeal tissue was completed, which identified necrotizing sialometaplasia. High clinical suspicion led to repeat deep-tissue biopsy, where a final diagnosis of NKTCL, nasal type was made. The patient then began definitive treatment with chemotherapy and radiation.
CONCLUSIONS: High clinical suspicion is key to early diagnosis and improved survival of NKTCL, nasal-type. Otolaryngologists who encounter prolonged, complicated cases of pharyngitis or necrotizing sialometaplasia should consider a diagnosis of NKTCL, nasal-type, in order to prevent rapid disease progression.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25304998     DOI: 10.1016/j.amjoto.2014.07.012

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  6 in total

Review 1.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Authors:  Bradley M Haverkos; Zenggang Pan; Alejandro A Gru; Aharon G Freud; Rachel Rabinovitch; Meng Xu-Welliver; Brad Otto; Carlos Barrionuevo; Robert A Baiocchi; Rosemary Rochford; Pierluigi Porcu
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 2.  Concurrent Epstein-Barr virus associated NK/T cell lymphoma after immunosuppressive therapy for aplastic anemia: report of a case and review of literature.

Authors:  Guangli Yin; Ying Ni; Zhengrui Xiao; Guangsheng He; Kourong Miao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 3.  Extranodal NK/T Cell Lymphoma, Nasal Type with Palatal Involvement: A Rare Case Report and Literature Review.

Authors:  Anastasia Andreou; Grigorios Thermos; Alexandra Sklavounou-Andrikopoulou
Journal:  Head Neck Pathol       Date:  2020-06-25

4.  Extranodal NK/T Cell Lymphoma with Destruction of the Uvulae: A Case Report.

Authors:  Farahzad Jabbari Azad; Zahra Delavarian; Masoud Hatami; Hosein Rahimi; Mohammad Reza Abdolvahed
Journal:  Iran J Otorhinolaryngol       Date:  2017-03

5.  Specific Soft-Tissue Invasion and LMP1 Expression Are Potential Indicators of Extranodal NK/T Cell Lymphoma, Nasal Type.

Authors:  Min Jiang; Haoyue Lu; Chao Lu; Xingdong Geng; Yingjun Jia; Peng Wang; Wei Qian; Hao Huang; Xiuhong Shan
Journal:  Med Sci Monit       Date:  2018-10-25

6.  Primary pulmonary extranodal NK/T-cell lymphoma: a case report and literature review.

Authors:  Yanli Wang; Zhengxia Wang; Chaojie Wu; Xinyun Zhao; Ningfei Ji; Mao Huang
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.